Table 5.
Clinical Use of Post-pruning CART.
| Input Variables | Most Common Treatment(s) No. of Patients (1-Year SR, %) |
Treatment with Highest SR No. of Patients (1-Year SR, %) |
Treatment with 2nd-Highest SR No. of Patients (1-Year SR, %) |
Treatment with 3rd-Highest SR No. of Patients (1-Year SR, %) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prediction | Group | Subgroup | n = 375 | 1-year Survival | AFP (mcg/L) |
GOT (µkat/L) |
T-bil (mmol/L) |
||||
| SR > 1 year | 1 | 102 | 78% | ≤210.5 | ≤1.13 | ≤0.0283 | Surgery 45 patients (44%) |
RFA 7 patients (100%) |
TACE + RT 1 patient (100%) |
Surgery 45 patients (82%) |
|
| SR ≤ 1 year | 2 | 2a | 4 | 0% | ≤210.5 | ≤1.13 | >0.0283 | TACE 1 patient (25%) ST 1 patient (25%) RT 1 patient (25%) IT 1 patient (25%) |
|||
| 2b | 82 | 40% | ≤210.5 | >1.13 | TACE 41 patients (50%) | RFA 1 patient (100%) TACE + RT + TDT 1 patient (100%) |
Surgery 20 patients (50%) RT 2 patients (50%) |
TACE 41 patients (41%) |
|||
| 2c | 187 | 22% | >210.5 | TACE 75 patients (40%) | RFA 1 patient (100%) TACE + TDT + IT 1 patient (100%) |
TACE + TDT 5 patients (60%) |
RT + TDT 2 patients (50%) |
||||
SR—survival rate; No.—Number of patients; RFA—radiofrequency ablation; TACE—transarterial chemoembolization; RT—radiation therapy; ST—symptomatic treatment (including palliative treatment); TDT—targeted drug therapy; IT—immunotherapy.